Business & Economy · 21 views
Nuvalent shares surge 39% after UK's GSK agrees to buy the drugmaker for $10.6 billion
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
Business & Economy 
Story intelligence
Coverage Single outlet Single-outlet story
Views 21 Community interest
Brief read Under 1 min brief 28 words
AI Summary
A significant development in the biotech industry has taken place with the announcement of a major acquisition. GSK has agreed to purchase Nuvalent, a drugmaker, for $10.6 billion.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
Part of GSK coverage 3 tracked stories
Explore GSK More from Business & Economy
Continue reading recent Business & Economy coverage
- U.S. stocks usually stumble after Fed hikes, but these markets tend to climb, says CitiContinue reading
- Dow futures fall 400 points to start shortened week as oil prices climb: Live updatesContinue reading
- No Luxury Spared: New High-End Cruise Ships Set SailContinue reading
- China’s Surging Exports Loom Over Trump’s Talks With XiContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow